Brian Mullaney,
MD, PhD

Chief Medical Officer

Brian MullaneyBrian has more than 20 years of experience in developing precision medicine, especially in the field of oncology.

Prior to joining Cornerstone, Brian was the Global Head of Clinical Affairs, Oncology Precision Medicine / Companion Diagnostics at Novartis; Senior Director, Oncology Translational Medicine at Eli Lilly; Director, Oncology Clinical Development at Bristol-Myers Squibb and Medical Director at Myriad Genetics

At Cornerstone, Brian is responsible for clinical development of Cornerstone’s platform technology. He will guide the clinical development of Cornerstone’s lead compound, CPI-613, as well as the other promising compounds in pipeline.

slider bt care differently

slider bt discovery

500 characters left
nysehome
videohome
videobutton

Know the Science behind

AEMD Platform
Read More >>
Slide item 1

Another Breakthrough
A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Read More >>
Slide item 2

People behind the Success

Our Team
Read More >>
Slide item 3
announcement1
announcement2
announcement3